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Transcriptional targets of the schizophrenia risk gene MIR137
AL Collins1, Y Kim1, RJ Bloom1, SN Kelada1, P Sethupathy1 and PF Sullivan1,2
Genome-wide association studies (GWAS) have strongly implicated MIR137 (the gene encoding the microRNA miR-137) in
schizophrenia. A parsimonious hypothesis is that a pathway regulated by miR-137 is important in the etiology of schizophrenia. Full
evaluation of this hypothesis requires more definitive knowledge about biological targets of miR-137, which is currently lacking. Our
goals were to expand knowledge of the biology of miR-137 by identifying its empirical targets, and to test whether the resulting
lists of direct and indirect targets were enriched for genes and pathways involved in risk for schizophrenia. We overexpressed
miR-137 in a human neural stem cell line and analyzed gene expression changes at 24 and 48 h using RNA sequencing. Following
miR-137 overexpression, 202 and 428 genes were differentially expressed after 24 and 48 h. Genes differentially expressed at 24 h
were enriched for transcription factors and cell cycle genes, and differential expression at 48 h affected a wider variety of pathways.
Pathways implicated in schizophrenia were upregulated in the 48 h findings (major histocompatibility complex, synapses, FMRP
interacting RNAs and calcium channels). Critically, differentially expressed genes at 48 h were enriched for smaller association P-
values in the largest published schizophrenia GWAS. This work provides empirical support for a role of miR-137 in the etiology of
schizophrenia.
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INTRODUCTION
Schizophrenia is now known to be highly polygenic with a genetic
architecture characterized by contributions from dozens and
probably hundreds of different genetic loci. Although rare
deleterious exonic and copy number variation (CNVs) have roles,
numerous common variants of more subtle effect account for
sizable fractions of the heritability of schizophrenia.1–4
A replicated and robust association with schizophrenia is in
MIR137, the gene encoding the microRNA miR-137. This region
was initially identified by the Psychiatric Genomics Consortium
(P= 1.6 × 10− 11).5 In the largest genome-wide association study
(GWAS) yet conducted (by the Psychiatric Genomics Consortium,
36 989 cases), the second strongest finding was within MIR137
(P= 3.4 × 10− 19).1 Pathway analyses have suggested that genes
containing predicted miR-137 target sites are significantly
enriched for smaller P-values for association with
schizophrenia.5–7 This enrichment is not robustly identified in all
studies,1 and one possibility is that miR-137 target predictions are
not sufficiently accurate.
It is possible that a pathway regulated by miR-137 is important
in the etiology of schizophrenia. microRNAs can target large
numbers of mRNAs for degradation or translational inhibition, and
a single microRNA can have major effects on cellular pathways.8–11
miR-137 has important roles in neural development12–15 and has
been implicated in autism, intellectual disability, Rett syndrome,
Alzheimer’s disease, Huntington’s disease and multiple
cancers.14,16–28
Schizophrenia GWAS results, pathway analyses and the roles of
miR-137 in development and disease are consistent with the
broad hypothesis that genetic variation in miR-137 and its targets
constitute a pathway whose dysfunction is involved in the
etiology of schizophrenia. There are several major limitations in
evaluating this hypothesis. A key issue is that miR-137 target
genes are mostly based on computational algorithms of imperfect
sensitivity and specificity. These algorithms predict only the direct
targets of miR-137.29,30 Some direct targets of miR-137 have been
verified12–14,18,25–28,31,32 including genes implicated in schizophre-
nia (CACNA1C, TCF4, CSMD1, C10orf26 and ZNF804A).33,34 However,
many of these targets were identified in cancers, and their
neuronal role is unclear. miRNA regulatory activity is complex and
can include regulatory loops, post-translational modifications and
non-canonical target sequences (for example, in coding regions
and not 3’ untranslated regions).15,35,36 The 'downstream' effects
of miR-137 (that is, its impact beyond a directly targeted
transcript) have not been systematically evaluated.
We thus evaluated the effects of miR-137 overexpression in a
human neuronal cell line. Our goal was to expand knowledge of
the biology of miR-137 by identifying its empirical targets. We
transduced neuronal stem cells with vectors expressing miR-137
or a control miRNA mimic and used high-throughput sequencing
(RNA-seq) at 24 and 48 h after transduction to assess the effects of
miR-137 overexpression. Overexpression of miR-137 had an
impact on multiple cell cycle genes, consistent with other findings
of effects on proliferation and downregulation in cancer. However,
we also found that the indirect effects of miR-137 overexpression
at 48 h had strong connections with GWAS findings for schizo-
phrenia. These results provide functional support for a role of
miR-137 in the etiology of schizophrenia.
MATERIALS AND METHODS
Cell line
ReNcell-VM (Millipore, Billerica, MA, USA) is a human neural precursor cell
line derived from the ventral mesencephalon.37 We chose this cell line
because it was readily available, accessible to our methods and not derived
from a cancer. Moreover, we genotyped two different clones with Illumina
OminExpress arrays and confirmed the expected male sex, European
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ancestry, the absence of aneuploidy and the absence of CNV larger than
4100 kb that affected a gene.
Infection of cells
ReNcell-VMs were grown on laminin-coated plates in ReNcell NSC
Maintenance Media (Millipore) with 20 ngml− 1 FGF-2 and 20 ngml− 1
epidermal growth factor. We used pEZX-MR03 lentiviral vectors with
miR-137 or a control packaged with an HIV-1-compatible system
(GeneCopoeia, Rockville, MD, USA). Infection efficiency was assessed by
microscopic evaluation of eGFP expression (contained in the pEZX-MR03
plasmid). To evaluate nonspecific effects because of overloading of the
miRNA-processing machinery, we used a control lentiviral vector contain-
ing a miRNA mimic (that is, a random miR-like sequence of no similarity to
any known miRNA). Flasks of cells were infected in parallel with the
miR-137 or control lentivirus. Viral amounts were titrated to achieve
~ 100% infection rates without evidence of toxicity. For the 48-h time
point, the cells were exposed to virus for 24 h and then replaced with fresh
media. Cells were collected 24 or 48 h after infection, stored in RNA-
stabilizing media (RNAlater, Qiagen, Venlo, The Netherlands) and frozen at
− 80 °C until analysis. Evaluation of two relatively early time points was
consistent with our goal of identifying the immediate effects of miR-137
overexpression as these are likely to be enriched for genes targeted by
miR-137.
RNA extraction
Total RNA was extracted using either Maxwell 16 LEV Simply RNA kit
(Madison, WI, USA; 24 h RNA-seq) or Norgen Biotek RNA/DNA/Protein Kit
(Thorold, ON, Canada; 48 h RNA-seq and mature miR-137 assays). Although
both methods yield total RNA, the Norgen kit extracts more mature
microRNAs (data not shown) and is better suited for quantification of
miR-137.
Quantitative PCR
We used TaqMan assays to measure expression of mature miR-137
(Applied Biosystems, assay ID 001129; Grand Island, NY, USA). Each sample
was run in quadruplicate, and StepOne software (v2.1; SAS, Cary, NC, USA)
was used to evaluate ΔCt and fold change (RQ) values. The endogenous
control was RNU6B. Statistical significance of the ΔCt values was assessed
using nested analysis of variance (SAS v9.2, PROC GLM). All assays were
performed on the same RNA samples as were used for RNA-seq except for
the miR-137 assays at the 24-h time point, which were carried out on
replicate samples (using RNA extracted with the Norgen kit).
RNA-seq
RNA-sequencing libraries were generated using Truseq RNA sample prep
kits (Illumina, San Diego, CA, USA), which generate libraries from poly-
adenylated RNAs. Each library was barcoded, pooled and sequenced using
Illumina HiSeq 2000 and single-end 100-bp reads. Single-end sequencing
was chosen to maximize read depth and detection of small fold changes.
There were three miR-137 overexpressions and three controls at 24 h, and
five miR-137 overexpressions and six controls at 48 h. Read depth
averaged ~ 55 million reads per replicate at 24 h and ~160 million reads
per replicate at 48 h (see below for explanation of greater numbers of
reads at 48 h). All procedures were randomized.
Data processing and analysis
We used the TopHat-Cufflinks-Cuffdiff pipeline to detect differential gene
expression between neural stem cells with increased expression of
miR-137 compared with controls. First, we used FastQC (see URLs) to
evaluate sequencing quality. As one 48-h sample failed, we repeated RNA-
seq on all of the 48-h samples. We verified sample identity across all
experiments via the creation of a vector of genotypes based on high-
confidence heterozygous exonic RNA-seq reads. RNA-seq reads were also
aligned to the overexpression sequence (miR-137 or a miR-like mimic) to
confirm experimental condition. Second, we mapped RNA-seq reads to the
human reference genome (UCSC hg19) using TopHat2 and transcript
annotations from the TopHat website (see URLs).38 Third, the mapped
reads were assembled into transcripts using Cufflinks (v2.0.1; http://
cufflinks.cbcb.umd.edu).39 Fourth, we pooled the Cufflinks output files
from multiple RNA-seq samples using Cuffcompare to assemble a
comprehensive set of transcripts. Finally, we used Cuffdiff39 to evaluate
differential gene expression of miR-137 overexpression versus the control
vector separately at 24 and 48 h with correction for multiple comparisons
using a false-discovery rate approach (q-value).40 We used the RNA-seq
data to evaluate gene expression of transcripts whose protein products are
known to characterize neuronal differentiation using a read count
approach (Supplementary Methods). A few genes were reported more
than once, and the transcript with the smallest P-value was retained.41
Additional analyses
We compared the effects of miR-137 overexpression in neural progenitor
cells to computational predictions of genes targeted by miR-137. We used
Sylarray (see URLs) to test all known miRNA seed sequences in the RNA-seq
gene level data.42 The analyses are performed at varying cutoffs to create a
curve of log10(P) values for each miRNA. We also compared differentially
expressed genes from miR-137 overexpression to computationally
predicted miR-137 targets (TargetScan v6.2; http://www.targetscan.org)43
with significance determined using permutation.
DAPPLE was used to evaluate whether the lists of genes had more
protein–protein interactions than predicted by chance.44 We used
DAVID45,46 to evaluate whether genes differentially expressed upon
miR-137 overexpression tended to occur in specific biological pathways
or processes including GO,47 KEGG48 and Biocarta (see URLs). DAVID
generated enrichment scores for correlated pathways and Benjamini
corrected P-values for individual pathways. PWM scan49,50 was used to
predict high-confidence transcription factor-binding sites in gene promo-
ters. We then identified transcription factor-binding site over-represented
in the promoters of significantly differentially expressed genes by Monte
Carlo simulation analysis.
We compared genes differentially expressed following miR-137 over-
expression to an analogous experiment by Hill et al.51 and to a gene
expression study in lymphoblastoid cell lines from schizophrenia cases and
controls.52 We evaluated the relevance of genes differentially expressed
following miR-137 overexpression to pathways previously implicated in the
etiology of schizophrenia: expert-curated lists of genes found at synapses
(1043 genes),53 genes encoding proteins found at the postsynaptic density
(1457 genes),54 genes in neuronal activity-regulated cytoskeleton-asso-
ciated protein postsynaptic signaling complexes (28 genes),55 N-methyl-D-
aspartate receptors (61 genes),55 L-voltage-gated calcium channel subunits
(26 genes),6 genes whose proteins interact with calcium channel (Cav2,
207 genes)56 and genes whose mRNAs interact with FMRP (fragile X mental
retardation protein, 842 genes).57
Finally, we assessed the overlap of genes differentially expressed
following miR-137 overexpression to schizophrenia GWAS results. This
analysis is a relatively direct evaluation of the salience of sets of genes
directly or indirectly regulated by miR-137 to genetic variation implicated
in the etiology of schizophrenia. We used INRICH58 to test whether
differentially expressed genes were enriched for smaller GWAS P-values in
the largest published schizophrenia GWAS6 (Supplementary Methods).
RESULTS
We transduced human neural precursor cells (ReNcell-VM) with
lentiviral vectors expressing either miR-137 or a scrambled miRNA-
like control. We verified infection rates 499% via fluorescent
imaging of the eGFP tag in the vector. Alignment of RNA-seq
reads to the lentiviral sequence confirmed correct expression of
the experimental vector in each sample.
Verification
We verified increased miR-137 expression in two ways. qPCR
confirmed marked increases in the amounts of mature miR-137 at
24 h (111x increase) and 48 h (548x increase) in cells exposed to
lentivirus expressing miR-137 compared with controls
(Supplementary Figure S1A). We used RNA-seq to estimate
expression of the primary poly-adenylated MIR137 transcript from
the miR-137 lentiviral vector and the MIR137 locus. Consistent with
the qPCR results, we found 123x increase in the primary transcript
at 24 h and 660x increase at 48 h (Supplementary Figure S1B).
As miR-137 can effect neuronal proliferation and
differentiation,12–14,59 we evaluated cell density, morphology and
expression of differentiation markers in the same flasks used for
miR-137 targets
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RNA-seq. There were no significant differences in cell densities
between miR-137 overexpression and control flasks at 24 (P= 0.53)
or 48 h (P= 0.78), although the 48-h flasks had higher cell densities
than at 24 h (P= 7.6 × 10− 9, as expected because of additional
growth time). We noted no qualitative differences in cellular
morphology between the experimental conditions at either time
point. We used RNA-seq to compare expression of 12 genes
whose protein products are commonly used to classify neuronal
cell types (Supplementary Table S1). There were no significant
differences between the miR-137 overexpression and control
conditions. The overall pattern of results is consistent with that of
a neuronal stem cell. Thus, large increases in expression of
miR-137 did not lead to clear alterations in cell fate after 24 or
48 h.
We verified the downregulation of predicted targets of miR-137
in two ways. First, we applied Sylarray42 to the RNA-seq data to
evaluate fold change differences associated with all known miRNA
seed sequences. Genes with the miR-137 seed sequence
(AGCAATTA) in the 3’-untranslated repeat evidenced the greatest
downregulation of any seed sequence (Supplementary Figure S1C,
minimum P= 1.1 × 10− 22 in the 24-h condition and minimum
P= 2.4 × 10− 45 in the 48-h condition). As a complementary test,
we used permutation to evaluate differential gene expression in
1115 genes with predicted miR-137 target sites (TargetScan
v6.2).43 Genes with a predicted miR-137 target site were
significantly more likely to be differentially expressed
(Supplementary Figure S1D, Po10− 200 at both 24 and 48 h),
and most were downregulated at 24 (82%) and 48 h (87%). These
results are consistent with profound and relatively specific
downregulation resulting from miR-137 overexpression.
General expression patterns
Supplementary Table S2 shows patterns of RNA-seq analyzability
at 24 and 48 h. After removing transcripts that had insufficient
sequencing depth, low expression levels or technical faults and
resolving genes reported more than once, there were 14 682
transcripts analyzable at both 24 and 48 h. The correlations
between miR-137 overexpression and control conditions were
0.999 at both 24 and 48 h, and the correlations between the 24
and 48 h conditions were 0.980–0.982 (Supplementary Figures S2a
and S2b). We applied principal component analysis to the
expression data matrix (Supplementary Figure S3). The first
principal component accounted for 97% of the variance and
completely distinguished the replicates from 24 and 48 h. These
descriptive results suggest the comparability of the RNA-seq data
within and between time points. The results also suggest that only
a fraction of transcripts was altered by the miR-137 experimental
manipulation.
Differential gene expression
Supplementary Figure S4 shows descriptive statistics for log2 fold
changes, P-values and q-values for the 24 and 48 h analyses. These
analyses compare the miR-137 overexpression to a control vector
within each time point. At 24 h, 14 869 unique genes were
analyzable and 202 (1.36%) had evidence of differential gene
expression (qo0.05, Supplementary Table S3). Of the differentially
expressed genes, 130 genes (64.4%) had evidence of inhibition of
gene expression following exposure to markedly elevated
amounts of miR-137 and 72 genes (35.6%) showed enhancement.
At 48 h, 428 (2.71%) of 15 780 analyzable and unique genes had
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Figure 1. Parallel plots of fold change values for the 14 694 analyzable genes at both 24 and 48 h. The four graphs are for each combination of
significance at 24 and 48 h time points (qo0.05). In each graph, the x axis shows fold changes (FCs) at 24 and 48 h time points, log2 (FC24) and
log2 (FC48). The y axis is log2 FC with positive values indicating upregulation upon overexpression of miR-137 and negative values the
opposite. Each line connects the log2 FC values for a gene. Large FC values may not be statistically significant (can occur when expression
levels are low). All lines in a are colored gray. For b–d, red lines indicate inhibition at both 24 and 48 h, green lines increased expression at
both 24 and 48 h and grey lines show genes whose log2 FC values switched signs between 24 and 48 h.
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S4). Of these, 157 genes (36.7%) showed inhibition after miR-137
overexpression and 271 genes (63.3%) showed enhancement.
Review of the read count data showed no instances where
miR-137 overexpression acted as a switch at either time point
(that is, high expression in the control condition and very low
expression with miR-137 overexpression). Differentially expressed
genes had subtler effects with transcriptional changes ranging
from 1.8-fold downregulation to 1.8-fold upregulation at 24 h and
from 2.9-fold downregulation to 2.8-fold upregulation at 48 h
(only 12 differentially expressed transcripts had fold changes in
excess of 2). Thus, despite substantial increases in miR-137
concentrations, the effects were quantitative not absolute and
consistent with a role for miR-137 acting to fine-tune gene
expression.
Figure 1 depicts full results from this study and lists of
differentially expressed genes are in Supplementary Tables S3
and S4. The results indicate the complexity of the effects of
miR-137 overexpression with time. For example, of transcripts that
were differentially expressed at both 24 and 48 h, only 44.1%
(15/34) had the same direction of effect each time.
We asserted above that the widely used, computationally
derived TargetScan (v6.2) list of miR-137 targets is imperfect. The
presence of a predicted TargetScan-binding site was associated
with significant (qo0.05) differential gene expression at 48 h
(odds ratio 4.0, 95% confidence interval (CI) 3.2–5.1,
P= 2.7 × 10− 33) and, as expected from the analyses above, this
was mainly because of inhibitory effects of miR-137 overexpres-
sion (odds ratio = 10.6, 95% CI 7.6–14.6, P= 6.4 × 10− 69) rather
than enhancement (odds ratio = 1.2, 95% CI 0.7–2.27, P= 0.52).
However, these strong statistical associations were not robustly
predictive as only 8.9% (87/1002) of analyzable genes with
predicted miR-137 target sites were differentially expressed and
only 20.3% (87/428) of differentially expressed transcripts had
predicted miR-137 target sites. The direct and indirect effects of
miR-137 thus appear to be complex and not robustly captured
using TargetScan.
Pathway analyses
As the effects of miR-137 overexpression influenced multiple
genes and never acted as a switch, we attempted to identify
biological themes that could unify the effects of miR-137 across
many different transcripts. We used a more liberal definition of
differential expression in these analyses (qo0.1 instead of 0.05).
We used DAPPLE44 to assess whether the protein products of
genes with significant differential expression had greater protein-
–protein interaction than expected by chance. We found
significantly more interactions at 24 h (P= 0.01) and at 48 h
(P= 0.001), and many of these genes formed a single network at
each time point (Supplementary Figure S5). This result is
consistent with the hypothesis that miR-137 influences multi-
component functional networks rather than targeting of unrelated
individual genes.
We applied pathway analysis to lists of differentially expressed
genes using DAVID (Table 1).45,46 At 24 h, genes with inhibition
after exposure to markedly increased amounts of miR-137
(presumably enriched for direct targets of miR-137) were enriched
for pathways related to extracellular matrix, positive regulation of
transcription, neuronal differentiation/projection and extracellular
signaling (Supplementary Table S5a). Genes with increased
expression at 24 h (presumptive indirect targets of miR-137) were
enriched for cell cycle consistent with prior reports
(Supplementary Table S5b).15,27,59 In the 48-h data, pathway
analysis of differentially expressed genes yielded more changes.
Interestingly, cell cycle pathways (upregulated at 24 h) were
strongly downregulated at 48 h (Supplementary Table S6a).
Pathways involved in DNA replication and cell cycle processes
were also downregulated at 48 h. Upregulated pathways at 48 h
Table 1. DAVID pathway analysis of differentially expressed genes (qo0.1)
Time Direction of effect Enrichment Annotation cluster description
24 h Downregulation (183 genes) 3.04 Extracellular matrix
2.92 Positive regulation of transcription
2.61 Neuron differentiation/projection
2.55 Extracellular signaling
Upregulation (126 genes) 2.75 Cell cycle
48 h Downregulation (239 genes) 10.75 Cell cycle
7.16 DNA replication
4.74 Lumen/membrane enclosed










4.18 MHC class II/antigen processing
3.89 Ion transport/gated channels
3.79 Immunoglobulin-like






Abbreviations: EGF, epidermal growth factor; MHC, major histocompatibility complex. Pathway analysis from DAVID. As many annotated pathways contain
overlapping genes, DAVID combines such pathways into clusters. Column 4 shows our labels for these clusters. Individual pathways are reported in
Supplementary Tables S5a and S6b.
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included strong enrichment for genes involved in multiple types
of cell–cell interactions, the major histocompatibility complex
class II antigens (a region containing the most significant GWAS
association for schizophrenia),5,6,60,61 synapses and ion channels/
calcium binding (Supplementary Table S6b).
Positive regulators of transcription were the second most
enriched cluster from the pathway analyses (Table 1), and four of
the most significantly enriched individual pathways from DAVID
involved transcriptional regulation (Supplementary Table S5a).
One of the top associations arising from schizophrenia GWAS is
TCF4, a transcription factor that contains two known miR-137-
binding sites.33 These results suggest that the effects of miR-137
can be extended markedly by altering the regulation of
transcription factors. To explore this possibility, we obtained a
list of 1745 genes encoding transcription factors from Transfac.62
At 24 h, 29 different transcription factors were downregulated
(qo0.1), slightly more than chance expectations (P= 0.01),
whereas there was no over-representation of transcription factors
in the upregulated genes (P= 0.61). At 48 h, genes encoding
transcription factors were less likely to be upregulated data
(P= 8.2 × 10− 4). These results are consistent with miR-137 acting
as an amplifier via directly fine-tuning the regulation of
transcription factors, which then leads to secondary regulatory
effects. TCF4 is a known direct target of miR-13733 and has been
implicated in schizophrenia GWAS.5,6 Although TCF4 was not itself
differentially expressed, we found enrichment for TCF4-bindings
sites in the promoters of genes with significant differential
expression at 48 h (P= 0.003), including both up- (P= 0.007) and
downregulation (P= 0.01). These results highlight the evident
complexity of miR-137 gene regulation and that effects on true
direct targets may not be detectable (due to transcriptional
repression or subtle effects) and yet influence transcription for
multiple genes.
Genomic studies of schizophrenia have implicated biological
pathways using multiple types of genomic data (common
variation, rare CNVs and rare exonic variation).3,6,55,63 It is possible
that genes influenced by miR-137 alter risk by directly or indirectly
targeting pathways central to pathogenesis. We thus evaluated
whether pathways implicated in schizophrenia were enriched for
transcripts with differential expression consequent to exposure to
increased amounts of miR-137. First, pathways including sets of
synaptic genes have been implicated in schizophrenia. Expert-
curated lists of synaptic genes are enriched for smaller GWAS
P-values,6,63 and genes encoding postsynaptic density proteins,
N-methyl-D-aspartate receptors and activity-regulated cytoskele-
ton-associated protein complexes (activity-regulated
cytoskeleton-associated protein) have been implicated in schizo-
phrenia by studies of de novo CNV, de novo deleterious exome
variation and deleterious exome variation in cases and
controls.3,4,55 We tested for associations of these pathways with
genes with differential expression at 24 and 48 h (Table 2). None of
these pathways were associated in the 24-h data but three
showed significant associations in the 48-h data (all but N-methyl-
D-aspartate receptor genes). The associations for synaptic genes
were particularly strong. Intriguingly, the 48-h associations tended
to be in differentially expressed genes showing upregulation.
Second, genes encoding RNAs that interact with FMRP (the
protein product of FMR1)57 are enriched for smaller GWAS
P-values and deleterious exon mutations in schizophrenia.3 We
found significant association between genes whose RNAs interact
with FMRP with upregulated genes at 48 h, supporting the idea
that RNAs bound by FMRP are influenced by miR-137. Third,
neuronal calcium channel signaling has been implicated in
schizophrenia and bipolar disorder.6,6,64 We found significant
associations between calcium channel subunits with genes
upregulated at 48 h following exposure to markedly increased
amounts of miR-137. The analogous association with genes whose
protein products were identified as interacting with Cav2 (voltage-
gated calcium channel) was nominally significant.56 Overall, there
was little evidence of association between genes differentially
regulated by miR-137 at 24 h but relatively consistent associations
with upregulation at 48 h. It is plausible that indirect/upregulation
effects require longer exposure to increased levels of miR-137; this
Table 2. Analyses of pathways implicated by schizophrenia genome-wide studies
Pathway DE genes (qo0.1) 24 h 48 h
P OR (95% CI) P OR (95% CI)
Synaptic genes All 0.90 0.94 (0.57–1.56) 2.8 ×10−7 2.13 (1.63–2.78)
(1043 genes) Downregulated 0.86 0.85 (0.41–1.74) 1.0 0.95 (0.5–1.81)
Upregulated 0.70 1.11 (0.54–2.28) 3.2 ×10−8 2.54 (1.88–3.44)
Postsynaptic All 0.78 0.88 (0.49–1.58) 0.06 1.4 (0.99–1.99)
density Downregulated 1.0 0.86 (0.38–1.97) 0.39 0.63 (0.28–1.44)
(1457 genes) Upregulated 1.0 0.98 (0.43–2.24) 0.0049 1.82 (1.23–2.71)
ARC All 1.0 N/A 0.0096 5.51 (1.86–16.32)
(28 genes) Downregulated 1.0 N/A 0.20 4.96 (0.61–40.5)
Upregulated 1.0 N/A 0.03 5.03 (1.4–18.09)
NMDA receptor All 1.0 0.89 (0.12–6.45) 0.17 1.94 (0.7–5.38)
(61 genes) Downregulated 1.0 N/A 0.24 2.24 (0.53–9.43)
Upregulated 0.41 1.94 (0.26–14.27) 0.32 1.84 (0.43–7.88)
FMRP interactors All 0.08 1.49 (0.96–2.32) 4.7 ×10−5 1.92 (1.43–2.57)
(842 genes) Downregulated 0.07 1.61 (0.98–2.65) 0.71 1.13 (0.57–2.21)
Upregulated 1.0 0.84 (0.31–2.28) 1.5 ×10−4 1.98 (1.42–2.75)
Calcium channel All 1.0 N/A 0.0056 6.61 (2.19–19.97)
subunits Downregulated 1.0 N/A 1.0 N/A
(26 genes) Upregulated 1.0 N/A 0.0098 5.68 (1.84–17.52)
Cav2 interactors All 0.08 N/A 0.11 1.68 (0.9–3.1)
(207 genes) Downregulated 0.27 N/A 0.73 0.47 (0.06–3.36)
Upregulated 0.65 N/A 0.04 2.09 (1.08–4.05)
Abbreviations: ARC, neuronal activity-regulated cytoskeleton-associated protein postsynaptic signaling complexes; Cav2, voltage-gated calcium channel;
CI, confidence interval; DE, differentially expressed; FMRP, fragile X mental retardation protein; NMDA, N-methyl-D-aspartate; OR, odds ratio. Boldface shows
Po0.01.
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supports a role for miR-137 as an effector that indirectly regulates
pathways critical to schizophrenia.
We compared these results with those of a similar experiment
by Hill et al.51 (~1000-fold increase in miR-137 expression in the
neural cell line CTXOE03, gene expression measured at 72 h using
Illumina HT-12v4 arrays). For the genes present in both studies,
there was a significant negative correlation in the log2 fold change
values at 24 h (Spearman ρ=− 0.33, P= 5× 10− 19) and a
significant positive correlation at 48 h (Spearman ρ= 0.25,
P= 3× 10− 11). Despite the use of a different vector, cell line and
expression technology, these results are surprisingly comparable
to these in our experiment. However, there was no significant
overlap between our results and genes that were differentially
expressing in lymphoblastoid cell lines from schizophrenia cases
and controls (data not shown).52
Schizophrenia GWAS results
Previous work has shown significant enrichment of smaller
schizophrenia GWAS P-values for predicted targets of miR-137.5,6
However, these analyses were based on TargetScan-predicted
direct effects of miR-137 which, as described above, have
incomplete overlap with the biological direct and indirect effects
of miR-137 overexpression in human neural precursor cells. We
thus compared the empirical findings from this report with results
from the largest published schizophrenia GWAS (Table 3).7 There
was no significant enrichment for genes differentially expressed at
24 h. However, there was significant enrichment of smaller GWAS
P-values for downregulated targets of miR-137.
DISCUSSION
miR-137 is a particularly intriguing association for schizophrenia,
given the strength of its association and the co-occurrence of
additional associations in many of its predicted targets. These
empirical findings from unbiased genomic screens are consistent
with the hypothesis that a biological or developmental process
orchestrated by miR-137 contributes to the etiology of schizo-
phrenia. As we demonstrated, a key limitation of our current
knowledge is that we have only an approximate idea of the genes
influenced by miR-137 (computational prediction of direct targets
using TargetScan and almost nothing on its indirect targets).
As an initial approach to understanding the reach of miR-137,
we overexpressed miR-137 in human neuronal stem cells to detect
genes whose transcripts showed differential expression upon
exposure to large increases in amounts of miR-137. Notably, our
results had approximate overlap with a similar study.51 Using a
number of verification analyses, we demonstrated that we
successfully increased the amounts of miR-137 and that these
effects were relatively specific. Our approach allowed detection of
direct targets influenced by RNA degradation plus secondary
effects in the form of increased expression. Via identification of
individual genes and larger-scale alterations in biological path-
ways, our findings provide a window into the cellular mechanisms
regulated by miR-137 in neuronal stem cells. Moreover, the
different patterns of findings at 24 and 48 h highlight the dynamic
regulation of miR-137, and emphasize that findings at a single
time point may not encompass all targets of a given miRNA. In
aggregate, these admittedly circumstantial results increase sup-
port for a role of miR-137 in schizophrenia.
First, the direct and indirect targets of miR-137 that we
identified had relatively small changes in expression, typically
less than twofold. We identified no instances where miR-137 acted
as an on- or off-switch. These findings are consistent with prior
studies showing that microRNAs yield subtle changes in many
genes.10,11 Moreover, many differentially expressed genes were
not predicted targets of miR-137, and many predicted targets are
not altered. We do not believe that this was be due to off target
effects or secondary effects on different microRNAs, given that
Sylarray detected only enrichment in miR-137 seed sequences
(Supplementary Figure S1C).
Second, miR-137 has been shown to affect proliferation and
differentiation.14,25,26,59 We found that cell density, morphology
and neuronal fate markers were not altered by miR-137 at 24 or
48 h. Given that cell cycle genes showed differential expression
(Table 1), it is possible that longer periods of observation would
have detected alterations in morphology or cell fate.
Third, our results were consistent with the coordinated
influence of miR-137 on multiple sets of functionally intercon-
nected genes (for example, via the significant enrichment of
protein–protein interactions in the differentially expressed genes
and the pathway analyses). These results support the hypothesis
that miR-137 causes subtle differential regulation of multiple
genes in interrelated pathways, leading to larger physiological
changes to a cell or organism.
Fourth, as summarized above, highly significant schizophrenia
GWAS findings near MIR137 and enrichment of its predicted
targets support a role of MIR137 in schizophrenia. However, the
region of association includes other candidate genes (DPYD and
MIR2682). Critically, genes influenced by miR-137 in a human
neural stem cell line (particularly downregulated genes) were
enriched for smaller GWAS P-values (Table 3). Moreover, pathway
analyses provide supporting data. Genes upregulated at 48 h
(presumptive indirect targets) were consistently enriched for
genes and pathways related to schizophrenia (Tables 1 and 2).
These included significant overlap with major histocompatibility
complex class II genes (encompassed by the strongest schizo-
phrenia finding to date), genes with TCF4 (a schizophrenia risk
locus and known target of miR-137) promoter-binding sites and
pathways previously implicated in schizophrenia (synaptic genes,
genes whose mRNAs interact with FMRP and L-type voltage-gated
calcium channels).
These results should be interpreted in the context of several
limitations. First, we are cautious in our comparison of results
between 24 and 48 h, given the change to a different method of
RNA extraction. Second, we attempted to sequester miR-137 as an
inhibition control but were unable to obtain technically satisfac-
tory results. Third, the degree of overexpression of miR-137 was
continual and far greater the naturally occurring levels of
expression.
In summary, our results have identified genes and pathways
regulated through miR-137, supporting a role of miR-137 in fine-
tuning neuronally important pathways including cell cycle
regulation, L-type voltage-gated calcium channels, cell–cell
interactions and synaptic function. These results provide empirical
data supporting the hypothesis that direct and indirect miR-137
targets have roles in the etiology of schizophrenia.
Table 3. Enrichment of schizophrenia GWAS results and genes with
differential expression after overexpression of miR-137
Time DE genes (qo0.1) Enrichment P-value
24 h All 40.1
Downregulation 40.1
Upregulation 40.1
48 h All 0.014
Downregulation 0.005
Upregulation 0.011
Abbreviation: GWAS, genome-wide association study. P-values from INRICH
evaluating the enrichment of lower GWAS P-values (Po0.01)6 to
differentially expressed genes (qo0.1) from miR-137 overexpression. The
extended major histocompatibility complex region (chr6:25–34mb) was
excluded due to its high gene density, extended linkage disequilibrium
and strong GWAS signal in schizophrenia. Boldface shows Po0.01.
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